AtaGenix Laboratories
AtaGenix Laboratories
Release time: 2026-03-23 View volume: 2
Choosing the right antibody discovery platform is one of the most consequential decisions in a project. Hybridoma, single B cell, and phage display each offer distinct advantages in speed, affinity, diversity, and downstream flexibility. This guide compares all three to help you match platform to project goals.
Modern antibody discovery relies on three core technologies, each with a different underlying principle for isolating target-specific binders:
Hybridoma: Fuse immunized mouse/rat B cells with myeloma cells to create immortalized clones that secrete monoclonal antibodies indefinitely. The gold standard for renewable reagent supply. Typical timeline: ~59 days.
Single B Cell (e.g., Xten™ Mab): Directly isolate individual antigen-specific B cells from immunized animals, preserving native VH/VL pairing. No fusion step required. Faster than hybridoma (~45 days) with access to the full natural repertoire.
Phage Display: Screen large combinatorial libraries (10⁸–10¹&sup0; clones) of antibody fragments (scFv or Fab) displayed on bacteriophage surfaces. Fully in vitro — no animal immunization required. Best for toxic antigens, human-origin antibodies, or targets with weak immunogenicity.
| Feature | Hybridoma | Single B Cell | Phage Display |
|---|---|---|---|
| Animal Immunization | Yes (mouse/rat) | Yes (mouse/rat/rabbit) | Optional (naïve or immunized library) |
| Typical Timeline | ~59 days | ~45 days | 8–12 weeks |
| VH/VL Pairing | Native (from single clone) | Native (preserved) | Artificial (combinatorial) |
| Library Diversity | Limited by fusion efficiency | Full natural repertoire | 10⁸–10¹&sup0; clones |
| Affinity Range | nM (in vivo matured) | nM–sub-nM | nM (may need maturation) |
| Species Origin | Mouse/rat | Mouse/rat/rabbit | Any (synthetic/human possible) |
| Renewable Cell Bank | Yes (hybridoma cells) | No (sequence-based) | No (sequence-based) |
| Best For | Long-term supply, diagnostics, matched pairs | Speed, rare clones, rabbit mAbs | Toxic targets, human antibodies, high diversity |
Choose Hybridoma When:
You need a renewable cell bank for long-term reagent supply, matched antibody pairs for sandwich ELISA or lateral flow, large-scale screening panels for diagnostics, or budget-sensitive projects where timeline flexibility exists.
Choose Single B Cell When:
Speed is critical (~45 days), you want native VH/VL pairing preserved, you need rabbit monoclonal antibodies, or you want to access rare clones that might be lost in hybridoma fusion.
Choose Phage Display When:
The antigen is toxic or poorly immunogenic, you need fully human antibodies without humanization, you want to screen massive diversity (10⁸+ clones), or the project requires in vitro selection against specific conformational states.
Yes. A common strategy is to use single B cell or phage display for initial discovery (fast, high-diversity screening), then convert top hits into recombinant expression for scale-up and characterization. Alternatively, hybridoma can be used as the primary discovery platform, with VH/VL sequencing enabling subsequent recombinant production and engineering (humanization, affinity maturation, bispecific construction). AtaGenix supports all three platforms and can recommend the optimal strategy based on your target, timeline, and downstream application requirements.
Not sure which platform fits your project? Share your target and application requirements — AtaGenix scientists will recommend the optimal discovery strategy within 24 hours.
Talk to Technical SupportResponse within 24 hours
Contact Us
+86-27-87001869
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
